| Bioactivity | Cimdelirsen is a novel, ligand-conjugated, hepatic-targeted investigative antisense oligonucleotide designed to reduce growth hormone receptor (GHr) synthesis, thereby inhibiting deleterious effects of growth hormone (GH) hypersecretion and reducing circulating insulin-like growth factor-1 (IGF-1) levels in acromegaly patients. |
| Name | Cimdelirsen sodium |
| CAS | 2131025-83-5 |
| Formula | C296H415N83Na20O152P20S15 |
| Molar Mass | 9128.16 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Bhanot S, Fleseriu M, Geary R, et al. OR27-4 Placebo-Controlled and Open-Label Extension Study of a Novel Hepatic-Targeted Antisense Cimdelirsen (IONIS-GHR-LRx) Under Investigation in Acromegaly Patients. J Endocr Soc. 2022;6(Suppl 1):A526. |
Cimdelirsen sodium
CAS: 2131025-83-5 F: C296H415N83Na20O152P20S15 W: 9128.16
Cimdelirsen is a novel, ligand-conjugated, hepatic-targeted investigative antisense oligonucleotide designed to reduce g
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.